Top

Journal of Cardiovascular Translational Research

Published in:

01-02-2021 | Ticagrelor | Methods Paper

Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale

The FABOLUS FASTER Trial

Authors: Giuseppe Gargiulo, Giovanni Esposito, Plinio Cirillo, Michael Nagler, Pietro Minuz, Gianluca Campo, Felice Gragnano, Negar Manavifar, Raffaele Piccolo, Marisa Avvedimento, Matteo Tebaldi, Andreas Wahl, Lukas Hunziker, Michael Billinger, Dik Heg, Stephan Windecker, Marco Valgimigli

Published in: Journal of Cardiovascular Translational Research | Issue 1/2021

Abstract

Antithrombotic therapy is a critical component of the management of ST-elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI). Rapid and profound inhibition of platelet reactivity has been shown to mitigate the ischemic risks and improve myocardial salvage. High residual platelet reactivity (HRPR) has been reported up to 4 or 6 h after loading dose of prasugrel or ticagrelor; therefore, multiple alternative strategies, including crushed or chewed oral tables or intravenous agents, have been investigated to provide a more rapid and sustained inhibition of platelet function and bridge the initial treatment gap. The FABOLUS FASTER is the first investigator-initiated, multicentre, open-label, prospective, randomized study to directly compare the pharmacodynamics effects of cangrelor, tirofiban, chewed or integer prasugrel. This study will add new insights in the management of antiplatelet therapy in patients with STEMI undergoing primary PCI and might be hypothesis-generating for future clinical trials in this field. The trial is registered on clinicaltrials.gov NCT02978040, and EudraCT 2017-001065-24.

Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., et al. (2018). 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 39(2), 119–177. https://doi.org/10.1093/eurheartj/ehx393.CrossRefPubMed

Neumann, F. J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., et al. (2019). 2018 ESC/EACTS guidelines on myocardial revascularization. European Heart Journal, 40(2), 87–165. https://doi.org/10.1093/eurheartj/ehy394.CrossRefPubMed

Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J. P., Costa, F., Jeppsson, A., et al. (2018). 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 39(3), 213–260. https://doi.org/10.1093/eurheartj/ehx419.CrossRefPubMed

Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., et al. (2016). 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Journal of the American College of Cardiology, 67(10), 1235–1250. https://doi.org/10.1016/j.jacc.2015.10.005.CrossRefPubMed

Davi, G., & Patrono, C. (2007). Platelet activation and atherothrombosis. The New England Journal of Medicine, 357(24), 2482–2494. https://doi.org/10.1056/NEJMra071014.CrossRefPubMed

Gargiulo, G., Moschovitis, A., Windecker, S., & Valgimigli, M. (2016). Developing drugs for use before, during and soon after percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 17(6), 803–818. https://doi.org/10.1517/14656566.2016.1145666.CrossRefPubMed

Alexopoulos, D., Xanthopoulou, I., Gkizas, V., Kassimis, G., Theodoropoulos, K. C., Makris, G., et al. (2012). Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circulation. Cardiovascular Interventions, 5(6), 797–804. https://doi.org/10.1161/CIRCINTERVENTIONS.112.972323.CrossRefPubMed

Parodi, G., Valenti, R., Bellandi, B., Migliorini, A., Marcucci, R., Comito, V., et al. (2013). Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. Journal of the American College of Cardiology, 61(15), 1601–1606. https://doi.org/10.1016/j.jacc.2013.01.024.CrossRefPubMed

Valgimigli, M., Tebaldi, M., Campo, G., Gambetti, S., Bristot, L., Monti, M., et al. (2012). Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC. Cardiovascular Interventions, 5(3), 268–277. https://doi.org/10.1016/j.jcin.2012.01.006.CrossRefPubMed

10.

Alexopoulos, D., Barampoutis, N., Gkizas, V., Vogiatzi, C., Tsigkas, G., Koutsogiannis, N., et al. (2016). Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic/pharmacodynamic study. Clinical Pharmacokinetics, 55(3), 359–367. https://doi.org/10.1007/s40262-015-0320-0.CrossRefPubMed

11.

Asher, E., Frydman, S., Katz, M., Regev, E., Sabbag, A., Mazin, I., et al. (2017). Chewing versus swallowing ticagrelor to accelerate platelet inhibition in acute coronary syndrome - the CHEERS study. For the PLATIS (platelets and thrombosis in Sheba) study group. Thrombosis and Haemostasis, 117(4), 727–733. https://doi.org/10.1160/TH16-09-0728.CrossRefPubMed

12.

Asher, E., Tal, S., Mazin, I., Abu-Much, A., Sabbag, A., Katz, M., et al. (2017). Effect of chewing vs swallowing ticagrelor on platelet inhibition in patients with ST-segment elevation myocardial infarction: a randomized clinical trial. JAMA Cardiology, 2(12), 1380–1384. https://doi.org/10.1001/jamacardio.2017.3868.CrossRefPubMedPubMedCentral

13.

Parodi, G., Xanthopoulou, I., Bellandi, B., Gkizas, V., Valenti, R., Karanikas, S., et al. (2015). Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. Journal of the American College of Cardiology, 65(5), 511–512. https://doi.org/10.1016/j.jacc.2014.08.056.CrossRefPubMed

14.

Rollini, F., Franchi, F., Hu, J., Kureti, M., Aggarwal, N., Durairaj, A., et al. (2016). Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. Journal of the American College of Cardiology, 67(17), 1994–2004. https://doi.org/10.1016/j.jacc.2016.02.045.CrossRefPubMed

15.

Serenelli, M., Pavasini, R., Vitali, F., Tonet, E., Bilotta, F., Parodi, G., et al. (2019). Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 17(6), 944–950. https://doi.org/10.1111/jth.14434.CrossRefPubMed

16.

Venetsanos, D., Sederholm Lawesson, S., Swahn, E., & Alfredsson, J. (2017). Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: the inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial. Thrombosis Research, 149, 88–94. https://doi.org/10.1016/j.thromres.2016.10.013.CrossRefPubMed

17.

Valgimigli, M., Biondi-Zoccai, G., Tebaldi, M., van’t Hof, A. W., Campo, G., Hamm, C., et al. (2010). Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. European Heart Journal, 31(1), 35–49. https://doi.org/10.1093/eurheartj/ehp376.CrossRefPubMed

18.

Akers, W. S., Oh, J. J., Oestreich, J. H., Ferraris, S., Wethington, M., & Steinhubl, S. R. (2010). Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. Journal of Clinical Pharmacology, 50(1), 27–35. https://doi.org/10.1177/0091270009344986.CrossRefPubMed

19.

Angiolillo, D. J., Schneider, D. J., Bhatt, D. L., French, W. J., Price, M. J., Saucedo, J. F., et al. (2012). Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. Journal of Thrombosis and Thrombolysis, 34(1), 44–55. https://doi.org/10.1007/s11239-012-0737-3.CrossRefPubMed

20.

Storey, R. F., Wilcox, R. G., & Heptinstall, S. (2002). Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets, 13(7), 407–413. https://doi.org/10.1080/0953710021000024402.CrossRefPubMed

21.

Storey, R. F., Oldroyd, K. G., & Wilcox, R. G. (2001). Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thrombosis and Haemostasis, 85(3), 401–407.CrossRef

22.

Greenbaum, A. B., Grines, C. L., Bittl, J. A., Becker, R. C., Kereiakes, D. J., Gilchrist, I. C., et al. (2006). Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. American Heart Journal, 151(3), 689 e681–689 e610. https://doi.org/10.1016/j.ahj.2005.11.014.CrossRef

23.

Bhatt, D. L., Lincoff, A. M., Gibson, C. M., Stone, G. W., McNulty, S., Montalescot, G., et al. (2009). Intravenous platelet blockade with cangrelor during PCI. The New England Journal of Medicine, 361(24), 2330–2341. https://doi.org/10.1056/NEJMoa0908629.CrossRefPubMed

24.

Harrington, R. A., Stone, G. W., McNulty, S., White, H. D., Lincoff, A. M., Gibson, C. M., et al. (2009). Platelet inhibition with cangrelor in patients undergoing PCI. The New England Journal of Medicine, 361(24), 2318–2329. https://doi.org/10.1056/NEJMoa0908628.CrossRefPubMed

25.

Angiolillo, D. J., Rollini, F., Storey, R. F., Bhatt, D. L., James, S., Schneider, D. J., et al. (2017). International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation, 136(20), 1955–1975. https://doi.org/10.1161/CIRCULATIONAHA.117.031164.CrossRefPubMed

26.

Franchi, F., Rollini, F., Rivas, A., Wali, M., Briceno, M., Agarwal, M., et al. (2019). Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation, 139(14), 1661–1670. https://doi.org/10.1161/CIRCULATIONAHA.118.038317.CrossRefPubMed

27.

Vaduganathan, M., Harrington, R. A., Stone, G. W., Deliargyris, E. N., Steg, P. G., Gibson, C. M., et al. (2017). Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb/IIIa inhibitors: an exploratory analysis from the CHAMPION trials. JAMA Cardiology, 2(2), 127–135. https://doi.org/10.1001/jamacardio.2016.4556.CrossRefPubMed

28.

Sibbing, D., Aradi, D., Alexopoulos, D., Ten Berg, J., Bhatt, D. L., Bonello, L., et al. (2019). Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC. Cardiovascular Interventions, 12(16), 1521–1537. https://doi.org/10.1016/j.jcin.2019.03.034.CrossRefPubMed

29.

Sibbing, D., Braun, S., Morath, T., Mehilli, J., Vogt, W., Schomig, A., et al. (2009). Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. Journal of the American College of Cardiology, 53(10), 849–856. https://doi.org/10.1016/j.jacc.2008.11.030.CrossRefPubMed

30.

Farid, N. A., McIntosh, M., Garofolo, F., Wong, E., Shwajch, A., Kennedy, M., et al. (2007). Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 21(2), 169–179. https://doi.org/10.1002/rcm.2813.CrossRefPubMed

31.

Bulluck, H., Dharmakumar, R., Arai, A. E., Berry, C., & Hausenloy, D. J. (2018). Cardiovascular magnetic resonance in acute ST-segment-elevation myocardial infarction: recent advances, controversies, and future directions. Circulation, 137(18), 1949–1964. https://doi.org/10.1161/CIRCULATIONAHA.117.030693.CrossRefPubMedPubMedCentral

32.

Ibanez, B., Aletras, A. H., Arai, A. E., Arheden, H., Bax, J., Berry, C., et al. (2019). Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel. Journal of the American College of Cardiology, 74(2), 238–256. https://doi.org/10.1016/j.jacc.2019.05.024.CrossRefPubMedPubMedCentral

33.

Gragnano, F., Spedicato, V., Frigoli, E., Gargiulo, G., Di Maio, D., Fimiani, F., et al. (2019). ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. Journal of Electrocardiology, 57, 44–54. https://doi.org/10.1016/j.jelectrocard.2019.08.045.CrossRefPubMed

Title: Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale
The FABOLUS FASTER Trial
Authors: Giuseppe Gargiulo
Giovanni Esposito
Plinio Cirillo
Michael Nagler
Pietro Minuz
Gianluca Campo
Felice Gragnano
Negar Manavifar
Raffaele Piccolo
Marisa Avvedimento
Matteo Tebaldi
Andreas Wahl
Lukas Hunziker
Michael Billinger
Dik Heg
Stephan Windecker
Marco Valgimigli
Publication date: 01-02-2021
Publisher: Springer US
Keywords: Ticagrelor
Tirofiban
Myocardial Infarction
Prasugrel
Published in: Journal of Cardiovascular Translational Research / Issue 1/2021
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-020-09969-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale

The FABOLUS FASTER Trial

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Diagnostic and Prognostic Value of Coronary Computed Tomography Angiography in Patients with Severe Calcification

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease

Effects of Colchicine on Atherosclerotic Plaque Stabilization: a Multimodality Imaging Study in an Animal Model

Immunomodulation of the NLRP3 Inflammasome in Atherosclerosis, Coronary Artery Disease, and Acute Myocardial Infarction

The Effect of Antihypertensive Therapy on Left Ventricular Longitudinal Strain: Missing Part of the Puzzle

Impact of Atrial Fibrillation on In-Hospital Mortality and Thromboembolic Complications after Left Ventricular Assist Device Implantation